Sign inJoin waitlistJoin the waitlist

Michael Nassif

Associate Professor of Medicine, University of Missouri-Kansas City · University of Missouri-Kansas City School of Medicine

Credentials: · · · · · ·

History

University of Missouri-Kansas City School of Medicine
Present

Fellowship/Research Saint Luke's Hospital
2015–2016
Cardiovascular Disease
Barnes-Jewish Hospital
2012–2015
Washington University/B-JH/SLCH Consortium
2009–2012
University of Iowa Roy J. and Lucille A. Carver College of Medicine
2005–2009

Research

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Nature Medicine · 2022 · 758 citations
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
Nature Medicine · 2021 · First of 26 authors · 504 citations
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
Circulation · 2019 · First of 27 authors · 342 citations

MK
Mikhail Kosiborod
31 papers
John Spertus
29 papers
SH
Stephen Heitner
24 papers
DJ
Daniel Jacoby
23 papers
FM
Fady Malik
23 papers
SK
Stuart Kupfer
23 papers
Ahmad Masri
22 papers
Martin Maron
22 papers
SL
Shane Larue
20 papers
SS
Scott Solomon
16 papers
Theodore Abraham
13 papers
Anjali Owens
12 papers

Clinical trials

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Site PI · Recruiting · Phase 4
Oregon Health and Science University
2026–2027
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Site PI · Recruiting
Endotronix, Inc.
2023–2033